Key insights
- Whitehawk Therapeutics CEO sold $49k in shares to cover tax obligations. The company also presented data on MUC16 expression in ovarian cancer, potentially impacting future therapeutic approaches. While the share sale itself is small, it adds to negative sentiment. However, the cancer data is a positive catalyst.
Whitehawk Therapeutics NASDAQ:WHWK Chief Executive Officer David James Lennon sold 14,500 shares of common stock on April 9, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The shares were sold at a price of $3.38, for a total transaction value of $49,010. Following the transaction, Lennon directly owns 518,622 shares of Whitehawk Therapeutics.
The sale was executed to satisfy tax withholding obligations related to the vesting of restricted stock units. According to InvestingPro analysis, the stock appears undervalued at current levels. Investors seeking deeper insights can access a comprehensive Pro Research Report on WHWK, part of the platform’s coverage of over 1,400 US equities.
In other recent news, Whitehawk Therapeutics Inc. presented data at the Society of Gynecologic Oncology 2026 Annual Meeting. The company showcased three posters highlighting the expression patterns of MUC16 in ovarian and endometrial cancers. This analysis, conducted in collaboration with Tempus AI, revealed that MUC16 expression in ovarian cancer is significantly higher, ranging from 2- to over 100-fold, compared to other ADC targets like NaPi2b, HER2, and others. The findings indicate that MUC16 maintains stable expression across various stages of the disease, including metastatic status and platinum sensitivity. This development is crucial as high-grade serous ovarian carcinoma, which represents about 70% of ovarian cancer cases, shows consistent MUC16 expression. Such data could have implications for future therapeutic approaches targeting MUC16 in ovarian cancer treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.